Browsing by Author "Restrepo Erazo, Katherine"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Late-onset Sheehan’s syndrome: a major diagnostic challenge—a case report(BioMed Central Ltd, 2025-02-26) Osorio Toro, Luis Miguel; Ordoñez Guzman, Yessica Alejandra; Montenegro Palacios, Jhon Fernando; Quintana Ospina, Jhon Herney; Pacichana Abadia, Julian Andres; Daza Arana, Jorge Enrique; Escobar Vargas, Hector Fabio; Restrepo Erazo, Katherine; García Ramos, Andrés FelipeBackground Sheehan’s syndrome is a form of maternal hypopituitarism resulting from excessive blood loss during or after childbirth. This extensive bleeding may reduce blood flow to the pituitary gland, causing pituitary cell damage and death (necrosis). The incidence of Sheehan’s syndrome has decreased in developed countries, whereas in developing countries, it remains a substantial cause of morbidity and mortality among at-risk populations. Case presentation We describe the case of a 59-year-old patient of mestizo ethnicity, with an unusual presentation of Sheehan’s syndrome 38 years after postpartum hemorrhage that affected hormone secretion at the adenohypophysis. During hospitalization, central adrenal insufficiency, low free thyroxine levels, decreased pituitary gland size, hypogonadotropic hypogonadism, and growth hormone deficiency were noted. The patient was treated with hydrocortisone and levothyroxine, with satisfactory clinical progress and improvement in her quality of life.Item Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study(Dove Medical Press Ltd, 2024) Balcázar Valencia, Carlos Mario; García Ramos, Andrés Felipe; Osorio Toro, Luis Miguel; Ordoñez Guzmán, Yessica Alejandra; Buitrago Gómez, Nathalia; Cabarcas López, William Fernando; Vizcaino Guerrero, Carlos Javier; Daza Arana, Jorge Enrique; Ramírez Rincón, Alex; Restrepo Erazo, KatherinePurpose: Diabetes is a public health problem that requires strategies to impact glycemic control and reduce the risk of long-term medical complications. Pharmacological management is a necessary treatment for this disease. Therefore, semaglutide is an essential tool to achieve the treatment targets. The present study aimed to evaluate the semaglutide effects on a cohort with type 2 diabetes mellitus (T2DM) in Colombia. Materials and Methods: The cohort included 49 patients with T2DM that have been treated in a specialized care center. Their glycemic outcomes, weight, renal function, and adverse events were evaluated through a 3-, 6-and 12-month follow-up. Results: Significant differences were observed in the outcome evaluation: reduction of glycated hemoglobin levels (MD −2.74 CI −1.95 to −3.52 in 6 months), fasting plasma glucose levels, body weight (MD −7.11 CI −5.97 to −8.24), and the albumin-to-creatinine ratio. The results were maintained throughout the treatment period. The adverse event rate was 16.3%, predominating gastrointestinal events. Conclusion: This real-world evidence shows the efficacy of semaglutide in achieving treatment goals in patients with T2DM.